This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Pharma IP rights are critical, trade group says

( December 21, 2018, 23:34 GMT | Official Statement) -- MLex Summary: Strong intellectual property rights are vital to the development of new drugs, an industry trade group said. "In the research-based biopharmaceutical industry, IP rights are critical to fostering innovation, ensuring continued R&D, and facilitating the successful transfer of technology," the Pharmaceutical Research and Manufacturers of America told the Federal Trade Commission in a public comment.See document below...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login